medetomidine
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 29, 2024 (NCT06262607)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
Chemistry & pharmacology
Loading structure…
SMILES
Cc1cccc(C(C)c2c[nH]cn2)c1C- Mol. weight
- 200.28 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL77921 ↗
- ChEMBLCHEMBL537161 ↗
Also known as
- dl-medetomidine
- medetomidine
- medetomidine
- (+/-)-medetomidine
- medetomidine hcl
- medetomidine hcl
- medetomidine hydrochloride
- medetomidine hydrochloride
- medetomidine hydrochloride
- medetomidine hydrochloride
- medetomidine hydrochloride
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06262607 | Phase 2 | Jan 29, 2024 | Clexio Biosciences Ltd. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Clexio Biosciences Ltd. | For profit | 1 | 1 | 1 | 2024 |
1 organizations
Page 1 / 1